CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Rivaroxaban for the treatment of cerebral venous thrombosis
Authors
S. Aarabi
M. Abolmaali
+6 more
S. Chaibakhsh
S. Esmaeili
M.T. Joghataei
Z. Mirzaasgari
M. Mojtahed
M.R. Motamed
Publication date
1 January 2021
Publisher
Abstract
Background: New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. Materials and methods: 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Result: Overall, 13 (36.11) patients received Warfarin and 23 (63.89) received Rivaroxaban. Optimal mRS score (0�1) was attained in 9 of 10 (90) of patients treated with Rivaroxaban and 19 of 22 (86.36) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Conclusion: Rivaroxaban holds promise for the treatment of CVT. © 2021, The Author(s)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
eprints Iran University of Medical Sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.iums.ac.ir:38937
Last time updated on 11/10/2021